doi: 10.3322/caac.21332 144 ChapmanPBHauschildARobertCHaanenJBAsciertoPLarkinJet al
Early-life LPS exposure induce microglial activation and triggers persistent DA neuron loss from infancy through adulthood, with maximal vulnerability observed at embryonic day 10.5a critical developmental window for DA neurogenesis (Zetterstrm et al., 1996)
For eligible adults with clinically significant obesity, MHRA-approved options include semaglutide (Wegovy, assessed in NICE TA875) and tirzepatide (Mounjaro, assessed in NICE TA1026), both available through NHS pathways with appropriate clinical oversight
PFHxS, PFOA groupings) PAHs (anthracene, pyrene, benzo derivatives) 3 Endocrine disruptors now front and centre Multiple entries classified as: ED HH 1 ED ENV 1 This is a major signal for downstream regulatory pressure
283 , 1134011347 (2008) Siu, F
Key Takeaways Retatrutide harnesses a triple-hormone approach to target metabolic function, potentially combating menopause weight gain and enhancing metabolic health